Focuses on ten product approvals through 2027
Expects to submit next-generation COVID vaccine for approval in 2024
Expects to submit flu/COVID combination vaccine for approval in 2024
Announces positive Phase 3 results for its RSV vaccine for high-risk adults aged 18 to 59; expects to submit sBLA for U.S. approval in 2024
Announces positive Phase 3 results for its standalone flu vaccine for adults aged 65 and older relative to high-dose licensed comparator
Announces norovirus vaccine advances into Phase 3 study, bringing the total of non-respiratory pivotal stage programs to five, across oncology, rare diseases and first-in-class vaccines
Implements portfolio prioritization and cost efficiencies to reduce R&D expense by $1.1 billion, from $4.8 billion in 2024E to $3.6-3.8 billion in 2027
Updates and extends financial framework through 2028
Read More
Folate receptor alpha targeting drug conjugate & hexa silanol exatecan (FRA-H) payloads tested in animal models of ovarian cancer
Strong efficacy for FRA-H in KB and IGROV-1 mouse models of ovarian cancer
Strong safety profile for FRA-H with no loss of bodyweight as compared with control in animal models
Success of tADC proof-of-concept study paves way for creating multiple potential therapeutic candidates for preclinical and clinical evaluation
-Proof of Concept Study in Rapid Acting GLP-1 to commence in October 2024 with data expected in November 2024
-Pre-clinical study to explore use of MODD1 pump as a personalized delivery system for people who discontinue long-acting GLP-1 formulations
-CEO to discuss further details of the program in Tribe Public Webinar on Wednesday, September 11 at 8:30 a.m. Pacific time
Read More
